SCI-004 MELCHRONO

A study of advanced melanoma examining the question: Does the effectiveness improve if immunotherapy is administered at specific times of day?

Coordinating Investigator

  • Berna Özdemir

    Berna Özdemir

    Oberärztin

People with advanced melanoma typically receive immunotherapy as standard treatment. The medications used are administered directly into the bloodstream via an intravenous infusion. Some analyses of patients treated with immunotherapy have suggested that the time of day when the drugs are administered may influence their effectiveness. It is believed that, particularly in women, effectiveness may depend on the time of day. However, it is not yet clear whether the time of day actually has an impact on treatment success. While some studies have shown a possible association, other studies have failed to demonstrate any effect of the time of day on the effectiveness of immunotherapy.

Therefore, further studies are needed to definitively answer this question. That is why, in this study, we are investigating whether individuals with advanced melanoma who receive immunotherapies at different times of day (morning or afternoon) experience different effects. We are particularly interested in:

  • Do treatment outcomes differ?
  • Do the side effects differ?
  • Are there differences between women and men?

In this study, participants will receive immunotherapy. The medications are approved in Switzerland for the treatment of melanoma. These medications are routinely used in clinical practice for many patients. Currently, the time of day when the medications may be most effective is not taken into account. The infusion therapy is administered at a time that is convenient for both the clinic and the patients.

Intervention Under Observation

All study participants will receive immunotherapy with one or two drugs. Various approved and authorized active ingredients will be used, such as nivolumab (Opdivo®), pembrolizumab (Keytruda®), ipilimumab (Yervoy®), and nivolumab and relatlimab (Opdualag®). The decision regarding a specific treatment is based on various factors, such as the number of metastases, the organs affected, and the patients’ overall health.

The infusions are administered every two to four weeks over a period of several months. Participants are divided into two groups:

  • Participants in Group 1 always receive immunotherapy between 8:00 a.m. and 12:00 p.m.
  • Participants in Group 2 always receive immunotherapy between 3:00 p.m. and 6:00 p.m. in the afternoon.

Inclusion Criteria

To participate in the study, a person must meet the following requirements:

  • She has advanced melanoma.
  • She meets the criteria for immunotherapy.
  • She is over 18 years old.

Exclusion Criteria

Individuals who meet any of the following criteria are not eligible to participate in the study:

  • The person had previously been treated with medication for cancer (with a few specific exceptions).
  • The person has undergone an organ transplant.
  • The melanoma is located in the eye or originates in the mucous membranes.

Hospitals

  • Inselspital - Universitätsspital Bern
    Inselspital - Universitätsspital Bern